Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 10/2012

01-10-2012 | Article

Initial dose of vancomycin based on body weight and creatinine clearance to minimize inadequate trough levels in Japanese adults

Authors: N. Maki, A. Ohkuchi, Y. Tashiro, M. R. Kim, M. Le, T. Sakamoto, S. Matsubara, Y. Hakamata

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 10/2012

Login to get access

Abstract

Our aims were to elucidate the factors that affected vancomycin (VCM) serum trough levels and to find the optimal initial dose based on creatinine clearance (CrCl) and body weight (BW) to minimize inadequate trough levels in a retrospective observational study among Japanese adults. One hundred and six inpatients, in whom VCM trough levels were measured after completing the third dosing, were consecutively recruited into our study in a tertiary hospital. We considered the frequency of <30% as low. In the generalized linear model, initial VCM total daily dose, CrCl, and BW were independent risk factors of VCM trough levels. In patients with CrCl ≥30 and <50 mL/min, 1 g/day yielded low frequencies of a trough level of ≥20 mcg/mL, regardless of BW. In patients with CrCl ≥50 mL/min, 2 g/day yielded low frequencies of a trough level of <10 mcg/mL in patients weighing <55 kg, but not in patients weighing ≥55 kg. Optimal VCM initial total daily dose may be 1 g/day in patients with CrCl ≥30 and <50 mL/min regardless of BW and 2 g/day in patients weighing <55 kg with CrCl ≥50 mL/min among Japanese adults.
Literature
2.
go back to reference Cook FV, Farrar WE Jr (1978) Vancomycin revisited. Ann Intern Med 88:813–818PubMed Cook FV, Farrar WE Jr (1978) Vancomycin revisited. Ann Intern Med 88:813–818PubMed
3.
go back to reference Bailie GR, Neal D (1988) Vancomycin ototoxicity and nephrotoxicity. A review. Med Toxicol Adverse Drug Exp 3:376–386PubMed Bailie GR, Neal D (1988) Vancomycin ototoxicity and nephrotoxicity. A review. Med Toxicol Adverse Drug Exp 3:376–386PubMed
4.
go back to reference Geraci JE, Heilman FR, Nichols DR, Wellman EW, Ross GT (1956) Some laboratory and clinical experiences with a new antibiotic, vancomycin. In: Welch H, Marti-Ibanez F (eds) Antibiotics annual 1956–1957. Medical Encyclopedia Inc., New York, pp 90–106 Geraci JE, Heilman FR, Nichols DR, Wellman EW, Ross GT (1956) Some laboratory and clinical experiences with a new antibiotic, vancomycin. In: Welch H, Marti-Ibanez F (eds) Antibiotics annual 1956–1957. Medical Encyclopedia Inc., New York, pp 90–106
5.
go back to reference Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedCrossRef Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedCrossRef
6.
go back to reference Llopis-Salvia P, Jiménez-Torres NV (2006) Population pharmacokinetic parameters of vancomycin in critically ill patients. J Clin Pharm Ther 31:447–454PubMedCrossRef Llopis-Salvia P, Jiménez-Torres NV (2006) Population pharmacokinetic parameters of vancomycin in critically ill patients. J Clin Pharm Ther 31:447–454PubMedCrossRef
7.
go back to reference Moellering RC Jr, Krogstad DJ, Greenblatt DJ (1981) Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 94:343–346PubMed Moellering RC Jr, Krogstad DJ, Greenblatt DJ (1981) Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 94:343–346PubMed
8.
go back to reference Matzke GR, McGory RW, Halstenson CE, Keane WF (1984) Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 25:433–437PubMedCrossRef Matzke GR, McGory RW, Halstenson CE, Keane WF (1984) Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 25:433–437PubMedCrossRef
9.
go back to reference Maeda Y, Omoda K, Fukuhara S, Ohta M, Ishii Y, Murakami T (2006) Evaluation of clinical efficacy of Maeda’s nomogram for vancomycin dosage adjustment in adult Japanese MRSA pneumonia patients. Drug Metab Pharmacokinet 21:54–60PubMedCrossRef Maeda Y, Omoda K, Fukuhara S, Ohta M, Ishii Y, Murakami T (2006) Evaluation of clinical efficacy of Maeda’s nomogram for vancomycin dosage adjustment in adult Japanese MRSA pneumonia patients. Drug Metab Pharmacokinet 21:54–60PubMedCrossRef
10.
go back to reference Lake KD, Peterson CD (1985) A simplified dosing method for initiating vancomycin therapy. Pharmacotherapy 5:340–344PubMed Lake KD, Peterson CD (1985) A simplified dosing method for initiating vancomycin therapy. Pharmacotherapy 5:340–344PubMed
11.
go back to reference Pryka RD, Rodvold KA, Erdman SM (1991) An updated comparison of drug dosing methods. Part IV: vancomycin. Clin Pharmacokinet 20:463–476PubMedCrossRef Pryka RD, Rodvold KA, Erdman SM (1991) An updated comparison of drug dosing methods. Part IV: vancomycin. Clin Pharmacokinet 20:463–476PubMedCrossRef
12.
go back to reference Cohen E, Dadashev A, Drucker M, Samra Z, Rubinstein E, Garty M (2002) Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patients. J Antimicrob Chemother 49:155–160PubMedCrossRef Cohen E, Dadashev A, Drucker M, Samra Z, Rubinstein E, Garty M (2002) Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patients. J Antimicrob Chemother 49:155–160PubMedCrossRef
13.
go back to reference Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP (2009) Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66:82–98. doi:10.2146/ajhp080434 PubMedCrossRef Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP (2009) Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66:82–98. doi:10.​2146/​ajhp080434 PubMedCrossRef
14.
go back to reference Tsuji BT, Rybak MJ, Lau KL, Sakoulas G (2007) Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus. Antimicrob Agents Chemother 51:1089–1091PubMedCrossRef Tsuji BT, Rybak MJ, Lau KL, Sakoulas G (2007) Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus. Antimicrob Agents Chemother 51:1089–1091PubMedCrossRef
15.
go back to reference Sakoulas G, Eliopoulos GM, Moellering RC Jr, Novick RP, Venkataraman L, Wennersten C, DeGirolami PC, Schwaber MJ, Gold HS (2003) Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J Infect Dis 187:929–938PubMedCrossRef Sakoulas G, Eliopoulos GM, Moellering RC Jr, Novick RP, Venkataraman L, Wennersten C, DeGirolami PC, Schwaber MJ, Gold HS (2003) Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J Infect Dis 187:929–938PubMedCrossRef
16.
go back to reference Murphy JE, Gillespie DE, Bateman CV (2006) Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parameters. Am J Health Syst Pharm 63:2365–2370PubMedCrossRef Murphy JE, Gillespie DE, Bateman CV (2006) Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parameters. Am J Health Syst Pharm 63:2365–2370PubMedCrossRef
17.
go back to reference Tajiri C, Yuasa S, Kabeya M, Aoki Y, Kawai M, Kusafuka H (2009) Comparison of predictive formulas of renal function for initial dose regimen of vancomycin hydrochloride: Cockcroft & Gault, Horio and Japanese Estimated GFR Formulas. Jpn J Ther Drug Monit 26:103–110 (in Japanese, abstract in English) Tajiri C, Yuasa S, Kabeya M, Aoki Y, Kawai M, Kusafuka H (2009) Comparison of predictive formulas of renal function for initial dose regimen of vancomycin hydrochloride: Cockcroft & Gault, Horio and Japanese Estimated GFR Formulas. Jpn J Ther Drug Monit 26:103–110 (in Japanese, abstract in English)
Metadata
Title
Initial dose of vancomycin based on body weight and creatinine clearance to minimize inadequate trough levels in Japanese adults
Authors
N. Maki
A. Ohkuchi
Y. Tashiro
M. R. Kim
M. Le
T. Sakamoto
S. Matsubara
Y. Hakamata
Publication date
01-10-2012
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 10/2012
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-012-1593-y

Other articles of this Issue 10/2012

European Journal of Clinical Microbiology & Infectious Diseases 10/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.